Fresh analysis suggests that patients who stop using popular slimming jabs like Mounjaro or Wegovy tend to recover reduced body mass far faster than those who end conventional lifestyle plans.
Findings released in a major health publication points out that while overweight individuals frequently drop a large proportion of their body weight while undergoing treatment, the mass is regained at an average rate of 0.8 kg per month once they quit.
"Users purchasing such drugs should be aware of the risk of fast rebound weight gain when the medication ends," stated researcher Dr. Susan Jebb.
That rate of regain means a return to pre-treatment mass in about one and a half years.
Comparing Approaches
The study, which looked at 37 of trials involving over 9,000 of patients, contrasted the results of these new drugs with other pills.
The team note that people who shed pounds through diet and exercise usually see a more gradual creep back—around 100 grams monthly—once they finish.
Understanding the Quick Regain
Nutrition scientists believe the mode of action of the drugs accounts for the amplified rebound.
GLP-1 drugs imitate a body's own chemical called GLP-1, which moderates appetite.
"Long-term administration of the hormone levels far above than normal might result in the body to produce less of its endogenous hormone, and could diminish sensitivity to its effects," explained Dr. Adam Collins, a nutrition expert.
"Discontinuation of this GLP-1 'fix' leads to hunger is no longer kept in check, making overeating far more likely."
A Chronic Disease?
The NHS suggest the jabs for people with weight-linked health risks, accompanied by recommended lifestyle changes.
Professionals contend that, due to the likelihood of weight regain, the treatment should be considered ongoing.
This perspective is echoed by pharmaceutical companies, who note that the findings "highlight the long-term nature of obesity," comparing it to managing conditions like hypertension.
User Testimonies
Individuals who have stopped the medication report a sudden resurgence of cravings.
"It was like a switch activating and you become ravenous," described one woman.
This challenge is exacerbated if users have not established permanent dietary or behavioural changes during therapy.
Growing Interest
Figures suggest that millions of people in the UK have tried these injections in the last 12 months, with interest continuing to grow.
- Adoption is greater among women compared to males.
- The middle-aged demographic shows the greatest level of interest.
- Many access the drugs through private prescriptions rather than the NHS.
Ultimately, researchers caution that while the jabs are potent tools for weight loss, they are not a permanent cure and lasting health benefits relies on ongoing lifestyle changes.
